- <![CDATA[REVELUTION-2 Trial Is Evaluating Cardiovascular Risk With Relugolix Plus Abiraterone Acetate in High-Risk Prostate Cancer]]><![CDATA[Sagar A. Patel, MD, discusses the REVELUTION-2 trial evaluating cardiovascular safety with hormone therapy in prostate cancer.]]>onclive · 2mo ago↗ source
- STAT+: BeOne wins FDA approval in lymphoma raceDiamantas takes the reins, Regenxbio stakes claim in Duchenne gene therapy, and more biotech news from The ReadoutSTAT · 2mo ago↗ source
- STAT+: Why big digital health players are missing from Medicare’s chronic care experimentIn this edition of STAT Health Tech: Why big digital health players skipped Medicare's ACCESS pilot, Isomorphic's big raise, and more.